Benefits
Common Cold Symptom Reduction
Zinc gluconate (and zinc acetate) lozenges, when started within 24 hours of cold symptom onset and dosed every 2 hours awake, shortened median symptom duration to 4.4 days versus 7.6 days on placebo (P<0.001) in the one randomized trial cited here (n=100, 50 zinc and 50 placebo). The 2017 meta-analysis cited here was published in JRSM Open and is not a Cochrane review; its stated conclusion is hedged, that properly composed zinc gluconate lozenges may be as effective as zinc acetate lozenges, and the estimate is imprecise (12 percentage points, 95% CI -12 to +36). Weigh the shorter cold against tolerability: 90% of the zinc group in that trial reported side effects. The FDA does not recognize a zinc and common cold health claim.
Good Bioavailability
The one pharmacokinetic study cited on this page (PMID 16372518, healthy men) compared zinc gluconate with zinc oxide and measured plasma zinc only (Cmax and AUC), with no health outcome. Systemic exposure was broadly similar between the two forms, so gluconate is a reasonable standard choice rather than a clearly superior one. Comparisons with citrate or bisglycinate are not covered by any reference on this page.
GI Tolerability
Zinc gluconate is often described as easier on the stomach than zinc sulfate, but no reference on this page compared the two salts for tolerability. What the cited cold trial does show is that the lozenge regimen was hard to tolerate, with 80% of the zinc group reporting bad taste and 20% reporting nausea. Nausea is more likely at high doses or on an empty stomach.
Skin and Acne (Not Studied on This Page)
Uncited. No reference listed on this page studied acne or any skin outcome, and the page carries no skin category. Treat this as a general statement about zinc rather than something the evidence below supports.
Cost-Effectiveness
Among the more affordable zinc forms while maintaining good bioavailability — popular choice for value-conscious consumers and budget multivitamins.
Mechanism of action
Cold Lozenge Mechanism
Zinc lozenges work via direct contact with throat mucosa — releasing zinc ions that interact with rhinovirus ICAM-1 binding sites and rhinovirus capsid, disrupting viral attachment and replication. This is a proposed mechanism, and none of the references on this page tested it directly. It depends on the lozenge dissolving slowly in the mouth, so swallowed capsules are not comparable and were not studied for this use in the cited work.
Gluconic Acid Carrier
Gluconic acid is a sugar acid (oxidized glucose). Zinc gluconate is well-soluble and absorbed via standard zinc transport mechanisms.
ICAM-1 Interaction (Antiviral)
Most rhinoviruses bind ICAM-1 (intercellular adhesion molecule-1) on respiratory epithelium for cell entry. Zinc ions have been proposed to interact with this receptor and with the viral capsid. That is a hypothesis for the shorter symptom duration seen in the cited trial, not something those studies measured.
Standard Zinc Enzyme Functions
Same enzyme cofactor and zinc finger transcription factor functions as other zinc forms.
Clinical trials
Two cited sources: a randomized, double-blind, placebo-controlled trial of zinc gluconate lozenges (Mossad 1996, Ann Intern Med, PMID 8678384), and a 2017 meta-analysis by Harri Hemila comparing zinc gluconate with zinc acetate lozenges (PMID 28515951). The 2017 paper was published in JRSM Open and is not a Cochrane review.
The randomized trial enrolled 100 participants, 50 assigned to zinc gluconate lozenges and 50 to placebo. The meta-analysis pooled previously published lozenge trials.
In the 1996 trial (n=100), median time to resolution of symptoms was 4.4 days with zinc gluconate lozenges versus 7.6 days with placebo (P<0.001). Tolerability was poor: 90% of the zinc group reported side effects, including 80% bad taste and 20% nausea. The 2017 meta-analysis found no significant difference between gluconate and acetate lozenges, but the estimate was imprecise (12 percentage points, 95% CI -12 to +36), and its authors concluded only that properly composed zinc gluconate lozenges may be as effective as zinc acetate lozenges. The frequently quoted 33% figure is not reported in either paper cited here. Dose caution: 13.3 mg every 2 hours while awake works out to roughly 80 to 100 mg of zinc per day, well above the 40 mg per day adult tolerable upper intake level, so this schedule is a short course of a few days, not an ongoing intake.
Single pharmacokinetic study in healthy men comparing zinc gluconate with zinc oxide (Siepmann 2005, Int J Clin Pharmacol Ther, PMID 16372518). This is one pharmacokinetic study, not an evidence review across human studies.
Healthy men in a single pharmacokinetic study, not a pool of trials. The number enrolled is not stated on this page.
Plasma zinc exposure (Cmax and AUC) was broadly comparable between zinc gluconate and zinc oxide. Plasma concentration is a laboratory measure, and no health outcome was assessed. Rankings against citrate or bisglycinate are not covered by this study or by any other reference on this page.